Search Results
Your search for all items matches 33990 pages
Showing 101 - 150TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
Lung Cancer Screening Model May Remove Barriers for Vulnerable Patients Residing in Central Texas
A new lung cancer screening initiative may help to overcome barriers to care among low-income, uninsured, and minority patients residing in Central Texas, according to a recent study published by Pignone et al in the American Journal of Preventive Medicine. The findings represented a critical step...
New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
Using computational tools, researchers have developed a novel method to assess which patients with metastatic triple-negative breast cancer may benefit from immunotherapy, according to a recent study published by Arulraj et al in the Proceedings of the National Academy of Sciences (PNAS)....
Use of Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC
Aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy as maintenance therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data presented at the International Association for the Study of Lung Cancer...
Addition of Lenvatinib to Ifosfamide/Etoposide in Children and Young Adults With Relapsed Osteosarcoma
In a phase II study (OLIE) reported in JAMA Oncology, Gaspar et al found that the addition of lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival in children or young adults with relapsed or refractory osteosarcoma. Study Details In the global open-label...
Addition of Cadonilimab to Platinum-Based Chemotherapy With or Without Bevacizumab in Cervical Cancer
In interim analyses of a Chinese phase III trial (COMPASSION-16) reported in The Lancet, Wu et al found that the addition of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, to platinum-based chemotherapy with or without bevacizumab significantly improved progression-free and overall...
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the BCR::ABL1 kinase inhibitor asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph-positive CML) in chronic phase. The FDA approval was granted on...
Ensuring an Inclusive Environment for Female Minority Oncologists
ASCO’s 2022 State of the Oncology Workforce in America report presented a dismal picture of the representation of Hispanic/Latinx oncologists in the field. According to the report, despite initiatives aimed at increasing diversity in the nearly 13,400 oncology workforce, which includes about 36%...
Distant Recurrence Risk Among Women With Early Breast Cancer Enrolled in Clinical Trials Between 1990 and 2009: EBCTCG Analysis
In an analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported in The Lancet, Hills et al found that risk of distant recurrence declined over time among women with early breast cancer enrolled in clinical trials between 1990 and 2009. Study Details The pooled analysis...
Association Between Pathologic Response and Relapse-Free Survival With Neoadjuvant Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
In an analysis reported in The Lancet Oncology, D’Alessio et al found that major pathologic response and complete pathologic response to neoadjuvant immune checkpoint inhibitor therapy was associated with improved relapse-free survival in patients with hepatocellular carcinoma. Study Details The...
Medicaid Expansion May Improve Cancer Care, Survival Among Patients With Hormone Receptor–Negative, HER2-Positive Breast Cancer
Patients with newly diagnosed hormone receptor–negative, HER2-positive breast cancer were more likely to receive timely, guideline-concordant treatment and experience longer survival in states participating in Medicaid expansion under the Affordable Care Act, according to a recent study published...
New Marker for Immunotherapy Response in Hepatocellular Carcinoma
A newly described stage of lymph node–like structures, known as tertiary lymphoid structures, identified in hepatic tumors following presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a recent study published by Shu et al in Nature...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Early Results Show Novel Agent Has Clinical Activity in FGFR3-Driven Advanced Bladder Cancer
In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....
Immunotherapy Plus Targeted Therapy for Anaplastic Thyroid Carcinoma
Researchers have demonstrated that anti–PD-L1 immunotherapy combined with mutation-directed targeted therapy may improve overall survival in patients with anaplastic thyroid carcinoma, according to a recent study published by Cabanillas et al in JAMA Oncology. Background Anaplastic thyroid...
Addition of Induction Chemotherapy to Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer. Study Details In the open-label trial,...
ECOG-ACRIN Cancer Research Group, Caris Life Sciences Partner to Learn More From TAILORx Trial
The ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a new multiyear research collaboration that will begin with the interrogation of the TAILORx trial. Background Breast cancer remains the most common cancer type in the United States, with approximately 310,720 new cases per...
Mutations and DNA Structures May Drive Urothelial Carcinoma
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
SBRT vs Conventional Radiotherapy for Localized Prostate Cancer
As reported in The New England Journal of Medicine by van As et al, the phase III PACE-B trial has shown noninferiority of stereotactic body radiotherapy (SBRT) vs conventionally fractionated radiotherapy in biochemical or clinical failure in patients with low- to intermediate-risk localized...
Impact of Hormonal Contraception on Breast Cancer Risk in BRCA1 and BRCA2 Germline Mutation Carriers
In a study reported in the Journal of Clinical Oncology, Phillips et al found that carriers of BRCA1—but not BRCA2—germline mutations who used hormonal contraception were at increased risk for developing breast cancer. Study Details The investigators used pooled data from four prospective cohort...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
Whole-Person Cancer Care: A Transformative Vision for Oncology
Guest Editor’s Note: Advances in cancer treatments have led to an increase in survival rates, but the quality of life is often diminished during survivorship. Because modifiable personal behavior contributes to health-care outcomes, interventions that support healthy behaviors may improve health...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes.1...
Risk of Subsequent Neoplasms in Survivors of Childhood Neuroblastoma
In a Dutch study reported in the Journal of Clinical Oncology, Westerveld et al identified long-term risks of subsequent neoplasms in 5-year survivors of childhood neuroblastoma. Study Details The study included data from 563 survivors in the Dutch Childhood Cancer Survivor Study–LATER cohort...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC). Study Details In the multicenter trial, 46...
New $3.3 Million NCI Grant May Facilitate Development of More Accurate, Comfortable Breast Cancer Screening Technology
The University of Arizona Health Sciences announced that it has received a $3.3 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to continue testing a novel imaging method for breast cancer detection that could provide an alternative to the mammogram....
MRI May Help Prevent Unnecessary Surgery in Patients With Rectal Cancer
Magnetic resonance imaging (MRI) may help patients with rectal cancer avoid invasive surgery and its potentially lifelong side effects, according to a recent study published by Williams et al in Radiology. Background “After undergoing chemotherapy and radiation for rectal cancer, patients are...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Meeting the Long-Term Challenge of Achieving Equity in Global Cancer Care
Although significant progress has been made against cancer, especially in the United States, which has seen the overall death rate from cancer fall by 33% over the past 3 decades, translating into averting an estimated 3.8 million deaths from the disease,1 progress worldwide has not been as...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More, Part 2
In the October 10, 2024, issue of The ASCO Post, we shared some unique insights from several recipients of the international development and education award (IDEA). As oncologists and cancer researchers from diverse low- and middle-income countries, their experiences at the 2024 ASCO Annual Meeting ...
Raising Awareness of the Health Consequences of Alcohol Consumption During and After a Cancer Diagnosis
In 2023, the World Health Organization (WHO) declared that “no level of alcohol consumption is safe for our health.”1 The warning came decades after the International Agency for Research on Cancer classified alcohol as a Group 1 carcinogen, which is the highest risk group, and also includes...
AMA House of Delegates Adopts ASCO-Sponsored Resolutions on Interpretation of Stark Law and Prior Authorization Costs
On September 23, 2024, the U.S. House of Representatives passed the Seniors’ Access to Critical Medications Act of 2024 (H.R. 5526), which would make permanent a waiver put in place during the COVID-19 pandemic that allowed Medicare patients to receive medications dispensed by in-office pharmacies...
Cancer Clinical Trials Continue to Be Out of Reach for Many Patients
Millions of Americans with cancer likely struggle to access some of the most advanced, state-of-the-art treatments being tested in clinical trials for their disease, according to a recent analysis from ASCO. The 2023 State of Cancer Care in America Snapshot and corresponding manuscript found 70% of ...
Outcomes With Adjuvant ICI Treatment in Resected Stage III/IV Melanoma
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Weber et al identified “cure rates” with adjuvant nivolumab, ipilimumab, and placebo in patients with resected stage III/IV melanoma. Study Details The analysis used mixture cure models (MCMs) to estimate cure rates ...
Cosmetic Outcomes With Two Schedules of Partial-Breast Irradiation in Early Breast Cancer
In the Canadian phase II OPAR trial reported in the Journal of Clinical Oncology, Kim et al found no difference in adverse cosmesis with partial breast irradiation (PBI) in five daily fractions of 30 Gy vs 27.5 Gy given over 1 week in patients with early breast cancer. The aim of the trial was to...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Heart Failure and Cancer: New Insights Into Reciprocal Relationship
Investigators have highlighted a critical connection between heart failure and cancer, demonstrating how shared mechanisms may contribute to the incidence and progression of both diseases, according to a recent scientific statement published by Bloom et al in the Journal of Cardiac Failure....
Listening to Music May Accelerate Postsurgical Recovery
Listening to music may accelerate postsurgical recovery, according to recent findings presented by Raees et al at the American College of Surgeons (ACS) Clinical Congress 2024. Background “When patients wake up after surgery, sometimes they feel really scared and don’t know where they are,”...
Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC
An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...
New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies
Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this rare but challenging subset of lung cancer cases. According to data presented at the...
Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC
The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...
Rogaratinib/Atezolizumab in Cisplatin-Ineligible FGFR mRNA-Overexpressing Urothelial Cancer
In the phase Ib FORT-2 trial reported in JAMA Oncology, Sweis et al found that the combination of the pan-FGFR inhibitor rogaratinib and atezolizumab was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer overexpressing FGFR mRNA. Study Details The study...
ACS Program May Reduce Postsurgical Mortality, Improve Care Among Older Patients
Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification program may reduce rates of postsurgical mortality and increase the proportion of patients with documentation standards such as advanced care directives, according to two new studies presented by Horattas et al and...
Cancer Diagnoses May Be Linked to Lasting Financial Challenges
Researchers have found that financial fallout can follow patients with cancer and their families as financial bankruptcy, lower credit scores, and other types of financial challenges in the years following a cancer diagnosis, according to two new studies presented by Gomez-Mayorga et al and...
Regorafenib in Refractory Advanced Gastric Cancer
As reported in the Journal of Clinical Oncology by Pavlakis et al, the phase III INTEGRATE IIa study showed improved overall survival with regorafenib plus best supportive care vs placebo vs best supportive care in patients with refractory advanced gastric/esophagogastric junction cancer. Study...
Three Days Was Enough
My dad agreed to receive hospice on a technicality. It happened after weeks of trying to get him home oxygen. My brother drove him to the oncologist’s office, and I helped him get into the wheelchair. He did not complain, but just asked me to hold his coffee mug, smiling because I snuck him a...
Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial
On October 18, Gilead Sciences announced its plans to voluntarily withdraw the U.S. accelerated approval for sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing...
FDA Approves Novel Combination for Gastric or Gastroesophageal Junction Adenocarcinoma
On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or...
